Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Trevi Therapeutics Inc has a consensus price target of $8.73 based on the ratings of 11 analysts. The high is $21 issued by EF Hutton on September 17, 2024. The low is $6 issued by HC Wainwright & Co. on August 30, 2024. The 3 most-recent analyst ratings were released by EF Hutton, Leerink Partners, and HC Wainwright & Co. on September 17, 2024, September 9, 2024, and August 30, 2024, respectively. With an average price target of $11.33 between EF Hutton, Leerink Partners, and HC Wainwright & Co., there's an implied 229.46% upside for Trevi Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Trevi Therapeutics (NASDAQ:TRVI) was reported by EF Hutton on September 17, 2024. The analyst firm set a price target for $21.00 expecting TRVI to rise to within 12 months (a possible 510.47% upside). 10 analyst firms have reported ratings in the last year.
The latest analyst rating for Trevi Therapeutics (NASDAQ:TRVI) was provided by EF Hutton, and Trevi Therapeutics maintained their buy rating.
There is no last upgrade for Trevi Therapeutics
There is no last downgrade for Trevi Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Trevi Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Trevi Therapeutics was filed on September 17, 2024 so you should expect the next rating to be made available sometime around September 17, 2025.
While ratings are subjective and will change, the latest Trevi Therapeutics (TRVI) rating was a maintained with a price target of $21.00 to $21.00. The current price Trevi Therapeutics (TRVI) is trading at is $3.44, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.